Data Sheet 4_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”

Data Sheet 7_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”

Data Sheet 11_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

“…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”

Data Sheet 5_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”

Data Sheet 2_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”

Data Sheet 10_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

“…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”

Data Sheet 12_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

“…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”

Data Sheet 6_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”

Relationship of different levels of physical activity on the health status of long-term breast cancer survivors: a cross-sectional study by Francisco Álvarez-Salvago (21338477)

“…This inactivity is significantly correlated with greater physical and emotional deterioration.…”

Combating Chemoresistance in Breast Cancer: Exploring Tumor Microenvironment, Combination Therapies, and Drug Repurposing Strategies by Shazia Sofi (17764488)

“…Chemoresistance in cancer can arise from a variety of molecular mechanisms, including active drug expulsion (drug efflux), decreased drug uptake, enhanced DNA repair mechanisms, the ability of cancer cells to evade programmed cell death (apoptosis), the diversity in the population of cancer cells within a tumor (tumor heterogeneity), and significant alterations in the tumor microenvironment (TME), where interactions between cancer cells, cancer-associated fibroblasts, immune cells, and the extracellular matrix contribute to a supportive environment that allows tumors to survive treatment and escape therapy. …”

Table 1_Overcoming tet(X)-harboring tigecycline resistance: a study on the efficacy of tigecycline-apramycin combinations.docx by Juan Liu (6492)

“…</p>Methods<p>In this study, we evaluated the synergism of tigecycline combining with other antibiotics as a means of overcoming the tet(X)-mediated resistance in Acinetobacter spp. …”

Table 3_Preliminary study on the time-correlation changes in brain neurotransmitters of mice exposed to mushroom toxin ibotenic acid.docx by Ruanxian Dai (21460028)

“…In the brain stem region, the tryptophan levels in each exposure group decreased significantly compared with the 4-h exposure group (P < 0.01), and brain stem choline levels significantly decreased (P < 0.05). …”

Table 5_Preliminary study on the time-correlation changes in brain neurotransmitters of mice exposed to mushroom toxin ibotenic acid.docx by Ruanxian Dai (21460028)

“…In the brain stem region, the tryptophan levels in each exposure group decreased significantly compared with the 4-h exposure group (P < 0.01), and brain stem choline levels significantly decreased (P < 0.05). …”

Table 2_Preliminary study on the time-correlation changes in brain neurotransmitters of mice exposed to mushroom toxin ibotenic acid.docx by Ruanxian Dai (21460028)

“…In the brain stem region, the tryptophan levels in each exposure group decreased significantly compared with the 4-h exposure group (P < 0.01), and brain stem choline levels significantly decreased (P < 0.05). …”

Table 1_Preliminary study on the time-correlation changes in brain neurotransmitters of mice exposed to mushroom toxin ibotenic acid.docx by Ruanxian Dai (21460028)

“…In the brain stem region, the tryptophan levels in each exposure group decreased significantly compared with the 4-h exposure group (P < 0.01), and brain stem choline levels significantly decreased (P < 0.05). …”

Table 4_Preliminary study on the time-correlation changes in brain neurotransmitters of mice exposed to mushroom toxin ibotenic acid.docx by Ruanxian Dai (21460028)

“…In the brain stem region, the tryptophan levels in each exposure group decreased significantly compared with the 4-h exposure group (P < 0.01), and brain stem choline levels significantly decreased (P < 0.05). …”

Table 1_Singing for memory: neural and cognitive effects of a choral intervention in older adults.docx by Miriam Napadow (17538380)

“…The study included examinations at three time points: T1, T2, and T3. A control period (T1-T2) was followed by the intervention period (T2-T3), each lasting approximately 11 months. …”

Table 1_Efficacy of the early start Denver model combined with the TEACCH program in children with autism spectrum disorder.docx by Ling-Ling Ma (7894544)

“…Cognitive scores on the PEP-3 improved by 11.31 points in the observation group compared to 8.15 in controls (P = 0.026). …”

Supplementary file 1_Healthy lifestyle moderates the association between recent negative life events and depressive symptoms: a cross-sectional study.docx by Yang Yang (45629)

“…., smoking status, drinking status, regular physical activity, sleep duration, and living alone), and was classified as unfavorable [0–2 points], intermediate [3 points], and favorable [4–5 points] groups. …”

Data Sheet 1_Dysregulation of melatonin rhythm in Parkinson’s and Huntington’s disease: a systematic review and meta-analysis.docx by Reema Priyanka Suram (22399759)

“…In manifest HD, both amplitude [RoM = 0.92, 95% CI (0.81 to 1.02); p = 0.00] and acrophase [RoM = 0.92, 95% CI (0.07 to 1.78); p = 0.03] significantly decreased. PD patients with sleep disorders had significantly higher melatonin concentrations than the non-sleep disorder group, with a significant test group difference of p = 0.00. …”